Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BOS BETTER ONLINE SOLUTIONS LTDBOSC · Entity 7418 | Director | March 18, 2026 | March 18, 2026 |
| Evogene Ltd.EVGN · Entity 8065 | Chief Financial Officer | March 18, 2026 | March 18, 2026 |
| Freightos LtdCRGO · Entity 7050 | Chief Financial Officer | September 01, 2026 | September 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BOS BETTER ONLINE SOLUTIONS LTD
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2029-08-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The options reported in this row vest and become exercisable over a period of three years from the August 20, 2024 vesting commencement date: 33.33% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (8.25% per quarter) over the following eight quarters such that all options will be fully vested and exercisable on the three-year anniversary of the vesting commencement date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options reported in this row vest and become exercisable over a period of three years from the August 20, 2024 vesting commencement date: 33.33% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (8.25% per quarter) over the following eight quarters such that all options will be fully vested and exercisable on the three-year anniversary of the vesting commencement date.
Evogene Ltd.
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary sharesSEC Table I · non-derivative | Direct | 4,100 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,100 F1: The ordinary shares reported in this row consist of 4,100 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person and that commenced vesting on April 1, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $12.58 · Expires 2032-03-30 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The options reported in this row vest and become exercisable over a period of four years from the March 30, 2022 vesting commencement date: 25% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date. |
| Stock Option (right to buy ordinary shares)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2034-11-20 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: The options reported in this row vest and become exercisable over a period of four years from the November 20, 2024 vesting commencement date, on an equal, quarterly basis (6.25% per quarter), such that they will be fully vested on the four-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of 4,100 ordinary shares underlying restricted share units ("RSUs") that were granted to the Reporting Person and that commenced vesting on April 1, 2023 and vest and become exercisable on an equal, quarterly basis (6.25% per quarter) over a four-year period such that they will be fully vested on the four-year anniversary of the grant date.
F2: The options reported in this row vest and become exercisable over a period of four years from the March 30, 2022 vesting commencement date: 25% of the options vested upon the one-year anniversary of the vesting commencement date, and the remaining options vest on an equal quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the vesting commencement date.
F3: The options reported in this row vest and become exercisable over a period of four years from the November 20, 2024 vesting commencement date, on an equal, quarterly basis (6.25% per quarter), such that they will be fully vested on the four-year anniversary of the grant date.
Freightos Ltd
Report date September 01, 2026 · Filed September 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 40,000 |
Reported balance
After 2026-09-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-01 · Grant · Acquired 40,000 · Balance 40,000 F1: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer. F2: The 40,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs in accordance with the following schedule: 33.33% of the RSUs will vest upon the one-year anniversary of the vesting commencement date (September 1, 2027), and the remaining RSUs will vest equally on a quarterly basis over the following eight quarters (8.3325% per quarter), such that all such 40,000 RSUs will be fully vested by the three-year anniversary of the vesting commencement date (September 1, 2029). |
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2026-09-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-01 · Grant · Acquired 20,000 · Balance 20,000 F1: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer. F3: The 20,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs, in their entirety, on December 31, 2028. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 20,000 |
Reported balance
After 2026-09-01 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-09-01 · Grant · Acquired 20,000 · Balance 20,000 F1: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer. F4: The 20,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs, in their entirety, on December 31, 2029. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer.
F2: The 40,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs in accordance with the following schedule: 33.33% of the RSUs will vest upon the one-year anniversary of the vesting commencement date (September 1, 2027), and the remaining RSUs will vest equally on a quarterly basis over the following eight quarters (8.3325% per quarter), such that all such 40,000 RSUs will be fully vested by the three-year anniversary of the vesting commencement date (September 1, 2029).
F3: The 20,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs, in their entirety, on December 31, 2028.
F4: The 20,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs, in their entirety, on December 31, 2029.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 01, 2026 Filed Sep 16, 2026 20:06 UTC | Freightos Ltd CRGO · Entity 7050 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-108252 · tm2624928-2_4seq1.xml · nonDerivative · entry 3 ELDAD YARON · CIK 0001408407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · security: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer. F4 · balance_after: The 20,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs, in their entirety, on December 31, 2029. Read SEC document |
| September 01, 2026 Filed Sep 16, 2026 20:06 UTC | Freightos Ltd CRGO · Entity 7050 | GrantOrdinary Shares | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-108252 · tm2624928-2_4seq1.xml · nonDerivative · entry 2 ELDAD YARON · CIK 0001408407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 F1 · security: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer. F3 · balance_after: The 20,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs, in their entirety, on December 31, 2028. Read SEC document |
| September 01, 2026 Filed Sep 16, 2026 20:06 UTC | Freightos Ltd CRGO · Entity 7050 | GrantOrdinary Shares | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-108252 · tm2624928-2_4seq1.xml · nonDerivative · entry 1 ELDAD YARON · CIK 0001408407 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 F1 · security: The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") granted to the Reporting Person by the Issuer. F2 · balance_after: The 40,000 ordinary shares reported in this row will be issuable upon vesting and settlement of RSUs in accordance with the following schedule: 33.33% of the RSUs will vest upon the one-year anniversary of the vesting commencement date (September 1, 2027), and the remaining RSUs will vest equally on a quarterly basis over the following eight quarters (8.3325% per quarter), such that all such 40,000 RSUs will be fully vested by the three-year anniversary of the vesting commencement date (September 1, 2029). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.